Literature DB >> 9731490

Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy.

G L Yount1, D A Haas-Kogan, K S Levine, K D Aldape, M A Israel.   

Abstract

Surgical resection followed by radiation therapy is the mainstay of treatment for glioblastoma multiforme (GBM), the most aggressive of the malignant gliomas. The poor clinical response of GBM and the intrinsic radiation resistance of this tumor type have prompted clinical investigations seeking to define the role of chemotherapy in the treatment of GBM. In this study, we examined the cytotoxic response of GBM-derived cell lines to treatment with both radiation and chemotherapy. We observed that the sensitivity of glioma cells to cisplatin- and FAS-induced apoptosis was diminished by prior treatment with ionizing radiation. Radiation conferred resistance to cisplatin and FAS cytotoxicity in a dose- and time-dependent manner. Radiation diminished the cisplatin-induced cytotoxicity of malignant glioma cells but failed to alter the cisplatin susceptibility of normal primary human astrocytes. Given the role of p53 in the response of cells to irradiation, we evaluated whether p53 function affects the observed radiation-induced resistance to cisplatin. By examining isogenic cell lines differing only in p53 function, we demonstrated that radiation conferred resistance to cisplatin independently of p53. Current clinical strategies in the treatment of astrocytic tumors, which include combined modality therapy, have been empirically derived from limited clinical experience. Further understanding of the molecular determinants of apoptosis associated with combined modality therapy may guide the design of more efficacious multimodality protocols.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731490

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration.

Authors:  Fabian Fehlauer; Martina Muench; Dirk Rades; Lukas J A Stalpers; Sieger Leenstra; Paul van der Valk; Ben Slotman; Ernst J Smid; Peter Sminia
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

2.  The antimicrotubule drug estramustine but not irradiation induces apoptosis in malignant glioma involving AKT and caspase pathways.

Authors:  Christina Vallbo; Tommy Bergenheim; Håkan Hedman; Roger Henriksson
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

3.  Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells.

Authors:  S Noda; S Yoshimura; M Sawada; T Naganawa; T Iwama; S Nakashima; N Sakai
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

4.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence.

Authors:  A Tsugu; K Sakai; P B Dirks; S Jung; R Weksberg; Y L Fei; S Mondal; S Ivanchuk; C Ackerley; P A Hamel; J T Rutka
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

5.  Decrease in Fas-induced apoptosis by the γ-secretase inhibitor is dependent on p75(NTR) in a glioblastoma cell line.

Authors:  Barbara Bessette; Karine Durand; Stéphanie Giraud; Gaëlle Bégaud; Muriel Mathonnet; Fabrice Lalloué
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

6.  The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells.

Authors:  Vesna Vucić; Ana Nićiforović; Miroslav Adzić; Marija B Radojcić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2007-12-04       Impact factor: 3.850

7.  Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice.

Authors:  Bradford A Perez; A Paiman Ghafoori; Chang-Lung Lee; Samuel M Johnston; Yifan Li; Jacob G Moroshek; Yan Ma; Sayan Mukherjee; Yongbaek Kim; Cristian T Badea; David G Kirsch
Journal:  Front Oncol       Date:  2013-04-02       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.